Synergistic activity of ALK and mTOR inhibitors for the treatment of NPM-ALK positive lymphoma
Sara Redaelli(University of Milano-Bicocca), Luca Mologni(Azienda Ospedaliera San Gerardo)
Cited by 28
Related Papers
Entrectinib, a Pan–TRK, ROS1, and ALK Inhibitor with Activity in Multiple Molecularly Defined Cancer Indications
|Molecular Cancer Therapeutics|2016|317
Activity of second‐generation ALK inhibitors against crizotinib‐resistant mutants in an NPM‐ALK model compared to EML4‐ALK
|Cancer Medicine|2015|88
Inhibition of RET tyrosine kinase by SU5416
|Journal of Molecular Endocrinology|2006|54